Irritable Bowel Syndrome Clinical Trial
Official title:
Recurrent Abdominal Pain in Children
The purpose of this study is to:
1. To determine if fiber versus placebo improves symptoms in children with recurrent
abdominal pain/irritable bowel syndrome.
2. To determine possible ways fiber or placebo improve(s) symptoms in children with
recurrent abdominal pain/irritable bowel syndrome by carrying out gastrointestinal
tests and questionnaires.
Understanding how diet and fiber affect GI function potentially will benefit the large
numbers of children with irritable bowel syndrome (IBS) and provide insight into prevention
of IBS in at risk children. We expect that the results from these studies can be used to
lessen significantly the huge financial burden to society caused by these chronic
conditions.
Consent will be obtained from the parent/guardian and assent from the child.
Children with recurrent abdominal pain (RAP) who meet the criteria for irritable bowel
syndrome (IBS) will be recruited and studied. They will have been diagnosed by a pediatric
gastroenterologist and will have had at least one healthcare visits in the past year for the
complaint of abdominal pain.
Coordinators will come out to the family's home on an evening that is convenient. Both the
parent and child will fill out some questionnaires. Next, the parent and child will get
instructions on how to fill out a diary to record any stomach pain the child is having and
what their stools look like. The child will also collect a stool sample during the regular
diet and diary collection period. Once the child has completed the diary, the child will go
on a special diet for eight days to remove foods that may cause stomach pain (foods and
drinks containing lactose, fructose, and sorbitol will be eliminated).
Two weeks later, the coordinators will come out to the family's home again to review the
pain and stool diary that the child kept while on the special diet. The coordinators will
explain how to collect some samples of urine, stool, and breath. These tests will evaluate
the gastrointestinal (GI) tract for inflammation and transit time. If the special diet does
not make the stomach pain go away, the child will be selected at random, like the flip of a
coin, to be placed in one of two groups: one group that receives fiber or one group that
receives a placebo or sugar pill. Fiber has been suggested to help children with stomach
pain.
After the child has been on the treatment for 6 weeks, he/she will keep another diary and
collect another set of samples of urine, stool, and breath.
The children will be followed at 3 months, 6 months and 18 months after the treatment
period.
Children will be asked to collect additional stools
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
| Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
| Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
| Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
| Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
| Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
| Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
| Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
| Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
| Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
| Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
| Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
| Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
| Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
| Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
| Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
| Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A | |
| Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 |